Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib: letters to the editor
Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
15 September 2015
|
| In: |
Leukemia
Year: 2015, Jahrgang: 29, Heft: 12, Pages: 2402-2404 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2015.245 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/leu.2015.245 Verlag, Volltext: https://www-nature-com.ezproxy.medma.uni-heidelberg.de/articles/leu2015245 
|
| Verfasserangaben: | K. Wenn, L. Tomala, S. Wilop, L. Vankann, C. Hasenbank, O. Frank, A. Hochhaus, F.J. Giles, T. Lange, M.C. Müller, S. Koschmieder, F. Beier, P. Ziegler, T.H. Brümmendorf |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1566311101 | ||
| 003 | DE-627 | ||
| 005 | 20230306100725.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171212s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/leu.2015.245 |2 doi | |
| 035 | |a (DE-627)1566311101 | ||
| 035 | |a (DE-576)496311107 | ||
| 035 | |a (DE-599)BSZ496311107 | ||
| 035 | |a (OCoLC)1340983444 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Wenn, K. |e VerfasserIn |0 (DE-588)1148476008 |0 (DE-627)1008745227 |0 (DE-576)49631100X |4 aut | |
| 245 | 1 | 0 | |a Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib |b letters to the editor |c K. Wenn, L. Tomala, S. Wilop, L. Vankann, C. Hasenbank, O. Frank, A. Hochhaus, F.J. Giles, T. Lange, M.C. Müller, S. Koschmieder, F. Beier, P. Ziegler, T.H. Brümmendorf |
| 264 | 1 | |c 15 September 2015 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 12.12.2017 | ||
| 520 | |a Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib | ||
| 700 | 1 | |a Müller, Martin Christian |d 1972- |e VerfasserIn |0 (DE-588)121360296 |0 (DE-627)705409236 |0 (DE-576)181482819 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 29(2015), 12, Seite 2402-2404 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib letters to the editor |
| 773 | 1 | 8 | |g volume:29 |g year:2015 |g number:12 |g pages:2402-2404 |g extent:3 |a Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib letters to the editor |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/leu.2015.245 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www-nature-com.ezproxy.medma.uni-heidelberg.de/articles/leu2015245 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171212 | ||
| 993 | |a Editorial | ||
| 994 | |a 2015 | ||
| 998 | |g 121360296 |a Müller, Martin Christian |m 121360296:Müller, Martin Christian |d 60000 |d 61200 |e 60000PM121360296 |e 61200PM121360296 |k 0/60000/ |k 1/60000/61200/ |p 10 | ||
| 999 | |a KXP-PPN1566311101 |e 2989779078 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["K. Wenn, L. Tomala, S. Wilop, L. Vankann, C. Hasenbank, O. Frank, A. Hochhaus, F.J. Giles, T. Lange, M.C. Müller, S. Koschmieder, F. Beier, P. Ziegler, T.H. Brümmendorf"]},"origin":[{"dateIssuedDisp":"15 September 2015","dateIssuedKey":"2015"}],"id":{"eki":["1566311101"],"doi":["10.1038/leu.2015.245"]},"physDesc":[{"extent":"3 S."}],"relHost":[{"title":[{"title":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title_sort":"Leukemia"}],"note":["Gesehen am 15.03.04"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib letters to the editorLeukemia","recId":"32046699X","language":["eng"],"pubHistory":["Nachgewiesen 11.1997 -"],"part":{"text":"29(2015), 12, Seite 2402-2404","volume":"29","extent":"3","year":"2015","issue":"12","pages":"2402-2404"},"origin":[{"dateIssuedDisp":"1997-","dateIssuedKey":"1997","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke"}],"id":{"issn":["1476-5551"],"zdb":["2008023-2"],"eki":["32046699X"]},"physDesc":[{"extent":"Online-Ressource"}]}],"person":[{"display":"Wenn, K.","roleDisplay":"VerfasserIn","role":"aut","family":"Wenn","given":"K."},{"given":"Martin Christian","family":"Müller","role":"aut","roleDisplay":"VerfasserIn","display":"Müller, Martin Christian"}],"title":[{"title":"Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib","subtitle":"letters to the editor","title_sort":"Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 12.12.2017"],"recId":"1566311101","language":["eng"]} | ||
| SRT | |a WENNKMUELLTELOMERELE1520 | ||